TY - JOUR
T1 - High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii
T2 - Using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen
AU - Shields, Ryan K.
AU - Kwak, Eun J.
AU - Potoski, Brian A.
AU - Doi, Yohei
AU - Adams-Haduch, Jennifer M.
AU - Silviera, Fernanda P.
AU - Toyoda, Yoshiya
AU - Pilewski, Joseph M.
AU - Crespo, Maria
AU - Pasculle, A. William
AU - Clancy, Cornelius J.
AU - Nguyen, M. Hong
N1 - Funding Information:
Experiments were conducted in the laboratories of Drs. Nguyen and Clancy at the University of Pittsburgh. The authors would like to thank Randy Smith, Senior Associate Dean of the School of Pharmacy, the University of Pittsburgh School of Pharmacy, and the University of Pittsburgh Department of Medicine for their generous financial support. We are also indebted to Kelley Wasicek and the Department of Pharmacy at the University of Pittsburgh for assistance in completing this study. Finally, we would like to extend our gratitude to Lloyd Clarke for his assistance with data collection and interpretation.
Funding Information:
Financial Support. The study was funded by the University of Pittsburgh School of Pharmacy and by seed support from the University of Pittsburgh, Department of Medicine to the Transplant Infectious Diseases Program (MHN and CJC).
PY - 2011/6
Y1 - 2011/6
N2 - Extensively drug-resistant (XDR) Acinetobacter baumannii infections caused 91% (10/11) mortality in transplant recipients. Isolates were colistin-susceptible initially, but susceptibility decreased during therapy in 40% (4/10). We tested antibiotic combinations against XDR Acinetobacter in vitro and demonstrated positive interactions for carbapenem-colistin. Subsequently, 80% (4/5) of transplant patients were treated successfully with carbepenem-colistin regimens.
AB - Extensively drug-resistant (XDR) Acinetobacter baumannii infections caused 91% (10/11) mortality in transplant recipients. Isolates were colistin-susceptible initially, but susceptibility decreased during therapy in 40% (4/10). We tested antibiotic combinations against XDR Acinetobacter in vitro and demonstrated positive interactions for carbapenem-colistin. Subsequently, 80% (4/5) of transplant patients were treated successfully with carbepenem-colistin regimens.
UR - http://www.scopus.com/inward/record.url?scp=79955963693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955963693&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2010.12.023
DO - 10.1016/j.diagmicrobio.2010.12.023
M3 - Article
C2 - 21353436
AN - SCOPUS:79955963693
SN - 0732-8893
VL - 70
SP - 246
EP - 252
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -
